"Be ready to catch the ball when it's thrown by life." Steve...

"Be ready to catch the ball when it's thrown by life."

Steve Jobs

My friends,

Tiresias sees the Optiscan share price. Tiresias understands the psychology of capital raisings. No existing shareholder likes them. That is no ordinary existing shareholder likes them. We want the price to go up. We want the price to go up without any capital input. We wanted it to go up last year, and we wanted it to go up last week and we want it to go up some more next week. Anything else, to the longstanding true believers, is a disappointment. Tiresias however sees what the cornerstone investors in Optiscan see. They see the raising as an opportunity the get some cheap stock. Tiresias also sees why they are right. Tiresias sees Optiscan’s revolutionary, real time, 3D, digital, in place and telepathology, at cellular magnification technology, that will transform pathology, transform cancer diagnosis, and transform cancer surgery and cancer management, going for a song. It is, my friends, a whole new paradigm. Unbelievable though, it is still hardly known. Tiresias, in his epistles, realises that he is preaching to the informed, some of whom have known of this technology for 20 years. They can't understand that nobody else knows about it and they can't understand why the price is so low. Well, Tiresias is equanimous. Tiresias sees what is in the offing. Tiresias see that, once the capital raising is over, Optiscan will have 19.5 million in cash. Tiresias sees the delayed FDA approval for oral oral medicine, for both the clinic for screening and diagnosis of oral lesions and oral cancer diagnosis, is imminent. This is a truly brand-new paradigm for which no equivalent exists. Its newness is the real reason for the delay in the FDA process. Similarly, Tiresias sees that from this moment, all oral surgery and all head and neck surgery will not be possible without an Optiscan laser endomicroscope in the operating theatre. If this doesn't launch it to the next level, the release of the breast-cancer study, which has been underway for some time, and which Tiresias is certain will show in vivo, paradigm shifting, digital photomicrographs of individual breast cancer cells, making the current breast cancer surgery obsolete and unethical without the presence and use of Optiscan’s microscope in every breast cancer operation in the world. Tiresias sees that we have, after the completion of the raising, a maximum of six months. So, my friends, Carpe Diem.

Carpe Diem.